Atherosclerosis modulates the electrophysiological effects of a peroxisome proliferator-activated receptor-gamma activator on pulmonary veins

International Journal of Cardiology

Volumn 145, Issue 3, 2010, Pages 578-582

  Cheng, Chen Chuan ^a   Pan, Nan Hung ^b   Chen, Yao Chang ^c   Yeh, Hung I ^e   Lin, Cheng I ^c   Chen, Shih Ann ^f   Chen, Yi Jen ^b,d  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e MACKAY MEMORIAL HOSPITAL   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Atherosclerosis; PPAR ; Pulmonary veins

Indexed keywords

APOLIPOPROTEIN E; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; ELECTRIC ACTIVITY; ELECTROSTIMULATION; HEART BEAT; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CONTRACTILITY; HEART RATE; LETTER; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PULMONARY VEIN; STREPTOZOCIN DIABETES; WILD TYPE;

EID: 78649926910     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.05.065     Document Type: Article

References (17)

1. W.M. Feinberg, J.L. Blackshear, A. Laupacis, R. Kronmal, and R.G. Hart Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 155 1995 469 473
2. N.H. Pan, H.M. Tsao, N.C. Chang, C.M. Lee, Y.J. Chen, and S.A. Chen Dilated left atrium and pulmonary veins in patients with calcified coronary artery: a potential contributor to the genesis of atrial fibrillation J Cardiovasc Electrophysiol 20 2009 153 158
3. E.I. Skalidis, M.I. Hamilos, and I.K. Karalis Isolated atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation J Am Coll Cardiol 51 2008 2053 2057
4. M. Haïssaguerre, P. Jaïs, and D.C. Shah Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins N Engl J Med 339 1998 659 666
5. Y.J. Chen, S.A. Chen, M.S. Chang, and C.I. Lin Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation Cardiovasc Res 48 2000 265 273
6. E.J. Benjamin, D. Levy, S.M. Vaziri, R.B. D'Agostino, A.J. Belanger, and P.A. Wolf Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study JAMA 271 1994 840 844
7. M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass The peroxisome proliferators-activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82
8. R.J. Aviles, D.O. Martin, and C. Apperson-Hansen Inflammation as a risk factor for atrial fibrillation Circulation 108 2003 3006 3010
9. M. Shimano, Y. Tsuji, and Y. Inden Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure Heart Rhythm 5 2008 451 459
10. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2007 2457 2471
11. P.M. Barger, and D.P. Kelly PPAR signaling in the control of cardiac energy metabolism Trends Cardiovasc Med 10 2000 238 245
12. J.A. Dormandy, B. Charbonnel, and D.J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
13. A.J. Edgley, P.G. Thalén, and B. Dahllöf PPARgamma agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats Eur J Pharmacol 538 2006 195 206
14. M.C. Granberry, J.B. Hawkins, and A.M. Franks Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure Am J Health Syst Pharm 64 2007 931 936
15. M. Dorkhan, M. Dencker, M. Stagmo, and L. Groop Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes Cardiovasc Diabetol 8 2009 8 15
16. J. Waugh, G.M. Keating, G.L. Plosker, S. Easthope, and D.M. Robinson Pioglitazone: a review of its use in type 2 diabetes mellitus Drugs 66 2006 340 341
17. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150